semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hypoglycemia Diabetes Mellitus Drug-Specific Antibodies Male or Female Person with diabetes (PWD) lives with or is in frequent contact with one or more caregivers who are available to administer the glucagon in case of an episode of severe or moderate hypoglycemia With a history of type 1 diabetes >1 year At least 18 years of age but not older than 75 years Body mass index (BMI) greater than or equal to 18.50 and below 35.00 kg/m2 PWD will be otherwise healthy according to medical history, general physical examination (including vital signs), nasal examination, and laboratory tests (biochemistry, hematology, and urinalysis) For female subjects, a urine pregnancy test must be negative  Presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma Use of a daily systemic beta-blockers, indomethacin, warfarin or anticholinergic drugs
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Low Milk Supply Pre-diabetes Insulin Resistance Suppressed Lactation among mother-infant dyads: Stage 1 (for participation in baseline measurement phase) identified with low milk supply by a Cincinnati-area IBCLC mother denies obvious cause of low milk supply such as pituitary disorder, breast surgery, severe lack of breast emptying (< 4 times per day), or failure to show any signs of lactogenesis mother at least 20 years of age infant is between 1 week and 2 calendar months old mother gave birth to a single, healthy, term (>37 weeks gestation) infant mother free of breast and nipple infections mother lives within study catchment area mother has not been diagnosed with Type 1 or Type 2 Diabetes Mellitus mother willing to sustain consistent use of herbal galactogogues (such as fenugreek) during follow up measurements (2-4 weeks) as was consumed during the baseline measurements
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-35.0,  Healthy Subjects will be healthy male volunteers who meet the below: Persons without clinically remarkable findings or clinically evident complications based on their concurrent illness, past medical history, physical examination, vital signs (blood pressure (BP), pulse rate (PR), and body temperature), 12-lead Electrocardiogram (ECG), and laboratory test results Persons who are 20 or older and 35 or younger Persons with a BMI 17.6 kg/m2 or more and 29.9 kg/m2 or less Persons who are willing to participate in this trial before study initiation and who give their written consent in accordance with GCP (Good Clinical Practice, MHW Ordinance No. 28 dated March 27, 1997)  Persons who deviate from the norm and who show clinical findings (BP, PR, and ECG) on consultation Persons with any clinically relevant complications Persons with gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immune, or hormonal disorders Persons with central nervous system disorders (e.g., epilepsy), mental disorders, or neurological disorders Persons with a history of significant orthostatic hypotension, syncopal attacks, or blackouts Persons with chronic infection or severe acute infection Persons with a history of severe allergy/hypersensitivity including allergies to drugs and inactive ingredients Persons who will have received a drug with a long half-life (more than 24 hours) within the month before treatment in this trial, within a period 10 times longer than the half-life of each drug, or during the study Persons who will have received a drug that may theoretically affect the study results based on the information obtained at the time of preparation of the protocol within the 10 days before treatment or during the study Persons who will have participated in another trial of an investigational drug within the 4 months before treatment or during the study
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-48.0,  Vitamin D Deficiency Gestation > 37 weeks Birth weight >2.5 kg Informed consent of one of the parents Place of residence<10km  Presence of gross congenital malformation Need of resuscitation at birth Need for admission to neonatal ICU Refusal of consent
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 5.0-51.0,  HIV HIV infection Ages 5.0 to 50.9 y In usual state of good health Subject and/or family commitment to the 12-week study  Other chronic health conditions unrelated to HIV/AIDS that may affect nutritional status Use of vit D supplementation above 400 IU/d
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-49.0,  Vitamin D Deficiency Subject is willing and able to give voluntary informed consent for participation in the study Ethnic group (Caucasian) Healthy males or females aged between 18 and 49 years old Normal weight (BMI 18.5-25kg/m2) Physical examination being assessed and accepted by the attending physician Systolic blood pressure within the normal range (90-140) mmHg Diastolic blood pressure within the normal range (60-90) mmHg Heart rate within the normal range (60-100 beats/min) Oral body temperature within the normal range (35.9 6 Cº)  The subject may not enter the study if ANY of the following apply Female subjects who is pregnant, lactating or planning pregnancy during the course of the study Ethnic group non Caucasian Males and Females aged <18 or >49 years old Underweight, overweight and obese Females and males Males and Females diagnosed with diabetes, hypothyroidism, hyperthyroidism, liver disease, renal dysfunction, cardiovascular diseases including hypertension, androgen-secreting tumor, Cushing syndrome, congenital adrenal hyperplasia, hyperprolactinemia, and/or virilism Known history or presence of food allergies or intolerance (e.g dairy products or gluten containing food), or any known condition that could interfere with the absorption, distribution, metabolism or execration of drugs History of drug or alcohol abuse, smoking of 10 cigarettes or more (or equivalent) per day Subjects who took medications known to affect metabolic parameters, such as metformin and corticosteroid drugs, vitamin D and calcium Participation in another clinical or bioequivalence study within 90 days prior to the start of this study period
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Autosomal Dominant Hypocalcemia (ADH) Subjects with a heterozygous activating mutation of the CaSR gene (ADH); if not previously confirmed, genetic testing will be performed at the screening visit At least 18 years of age Body mass index (BMI) ≥ 18.5 to < 39 kg/m2  Diseases or conditions that might compromise any major body system or interfere with the pharmacokinetics of NPSP795 History of treatment with PTH 1-84 or 1-34 within the previous 6 months History of hypocalcemia requiring frequent IV calcium infusions History of hypocalcemic seizure within the past 3 months Blood 25-hydroxy vitamin D level < 25 ng/mL. If subjects have a blood 25-hydroxy vitamin D level < 25 ng/mL at the outpatient screening visit, they will be prescribed vitamin D replacement. Once the 25-hydroxy vitamin D level is > 25 ng/mL, the subject will be eligible to continue on to the treatment phase of the study Estimated glomerular filtration rate (GFR) < 25 mL/minute, and/or abnormal hepatic, hematologic, and/or clotting function lead resting electrocardiogram (ECG) with clinically significant abnormalities Concomitant medications with the potential to interfere with NPSP795 metabolism History of thyroid or parathyroid surgery
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Obesity Pregnant Women >18 years old 22 weeks gestation BMI >= 25 cohabitating with partner for at least 3 months or recently married willing to consent Non-pregnant Partner BMI >= 25 cohabitating with partner for at least 3 months or recently married willing to consent  Untreated medical or psychological problem Inability to be physically active
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 45.0-75.0,  Osteoarthritis Must present with symptomatic chronic lower back pain due to OA for more than 3 months and having been diagnosed by a health care practitioner with OA They must have symptoms of OA such as pain and decreased range of motion, on subjective and physical examination and Participants must be receiving physiotherapy treatment from a specific and identified physiotherapist  Participants who are receiving any other forms of therapy other than physical therapy (massage and thermotherapy), for example osteopathy, acupuncture, ultrasound or electrotherapy as part of physiotherapy treatment Those presenting with acute lower back pain (with duration of only 3 months or less) and those suffering from chronic lower back pain as a result of disc herniation, compression fracture, lumbar spinal stenosis or spondylolisthesis
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 40.0-79.0,  Chronic Kidney Disease Cardiovascular Disease Age 40-79, women must be post-menopausal CKD stage IIIb or IV (estimated glomerular filtration rate by MDRD 15-45 mL/min/1.73m2), stable for 3 months Serum phosphorus 2.8-5.5 mg/dL, stable for 3 months Not using phosphate binders Albumin > 3.0 g/dL Free from alcohol dependence or abuse Ability to provide informed consent BMI < 40 kg/m2 Not taking medications that interact with agents administered during experimental sessions (e.g., sildenafil interacts with nitroglycerin) For 15-0384, completion of the prospective, randomized, placebo-controlled double-blind trial, Phosphorus Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease (COMIRB 13-0328) or completion of 12-week run-in phase  Life expectancy <1 year Uncontrolled hypertension History of severe liver disease History of congestive heart failure (EF < 35%) History of hospitalizations within the last 3 months History of ileus or bowel obstruction Active infection or antibiotic therapy Expected kidney transplant in the next 6 months Active vitamin D analogue use (i.e. calcitriol, paricalcitol, doxercalciferol) Vasculitis requiring immunosuppressive therapy within the last year
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Fatty Liver Nonalcoholic Steatohepatitis 18 years or older 2. Confirmed positive serology for HIV mono-infection 3. Valid Fibroscan/CAP results 4. Able to provide informed consent (available in French or English) 5. Receiving any approved antiretroviral regimen that does not contain integrase-inhibitor 6. Evidence of fatty liver (CAP>237.8dB/m) AND/OR evidence of significant liver fibrosis (Fibroscan > 8KPa) 7. HIV viral suppression (<50 copies/mL) for at least 6 months 8. No prior evidence of resistance to raltegravir or co-administered nucleoside backbone  Clinical evidence of decompensated liver disease at entry (e.g. ascites, bleeding esophageal varices, hepatic encephalopathy, or hepatoma/ hepatocellular carcinoma). 2. Co-infection with hepatitis C virus (HCV) or hepatitis C virus (HBV) (presence of serum HCV-Ab or HBsAg); 3. Alpha-fetoprotein (AFP) greater than or equal to 200 ng/mL at screening. 4. Known or suspected Wilson's disease, alpha-1-antitrypsin deficiency, celiac disease or other cause of chronic liver disease. 5. Chronic renal insufficiency (eGFR < 20 mL/min) at screening. 6. Pregnancy and planned pregnancy (not using adequate contraception). 7. Women who are breastfeeding. 8. Active opportunistic infection (except oral thrush) or neoplasm (except Kaposi's sarcoma, skin cancer, or cancer of the cervix or anus, unless known or suspected liver metastasis)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Vitamin D Deficiency Breastfeeding Available for enrollment within 2 weeks of delivery Residing in the study area in Ethiopia Apparently healthy  Self-reported chronic or acute disease condition Not breastfeeding Twin births
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Vitamin D Deficiency Vitamin D Insufficiency Patients approved for and undergoing clinically indicated bariatric surgery -Roux-en-Y Gastric Bypass (RYGBP) or Vertical Sleeve Gastrectomy (VSG) to 64 years of age BMI of 35 to 49.9 kg/m2 VitD insufficient pre-operatively: serum 25(OH)D concentration < 75 nmol/L or 30 ng/ml  Any patient who does not want to participate in the study Any patient who has dietary restrictions/proscriptions prohibiting ingestion of beef gelatin Expected poor compliance with the medical regimen Any active medical conditions that could, in the opinion of the investigators, jeopardize the safety of the subject or the integrity of the study The elective bariatric surgery is cancelled prior to incision by a surgeon for any reason Pregnancy: The routine standard of care is to determine whether a female patient is pregnant either by history and/or urinary pregnancy test on the day of surgery. No additional testing specifically for this study is planned beyond the standard of care
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Primary Dyslipidemia Chinese male or female 18 to 65 years old (inclusive). Fasting Serum TC: 5.18-6.21mmol/L (equals to 200-241 mg/dl) AND Serum TG: 1.7-5.65mmol/L (equals to 150- 500 mg/dl) for at least 1 time tested by central laboratory in the past 2 weeks prior to recruitment Primary dyslipidemia The subject demonstrates an understanding of the given information and ability to record the requested data Having obtained his/her informed consent  BMI above 32 kg/m2 ( morbid obesity) Pregnant or lactating women or intent to get pregnant Menopause women on hormonal replacement therapy Familial hyperlipidemia Identified food allergy to dairy product or lactose intolerance Severe diseases in heart, liver, kidney or hematopoietic system before admission History of angina, myocardial infarction, coronary artery bypass, heart failure or other cardiovascular instability during the last 6 months History of diabetes, GI, renal, pulmonary, hepatic and biliary, hypothyroidism, mental disease no self-control capacity or no articulate Subject who are currently taking drugs that interfere with lipid profiles, including but not limited to statin, nicotinic acid, bile acid sequestrant, fibric acids, policosanol tablets Subject who has received any anti-hyperlipidemia medication in the past 4 weeks
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 2.083-999.0,  Autosomal Dominant Hypophosphatemic Rickets FGF Mutation in either Arginine 176 or arginine 179 able and willing to provide consent or have a parent that is able/willing to consent, if a minor either serum iron <50mcg/dl (regardless of phosphate or intact FGF23 concentration); or iron between 500 and 100mcg/dl with serum phosphorus value below 3.0mg/dl for adults or less than or equal to 0.5 mg/dl the lower limit of normal for age in children and intact FGF23 about 30pg/ml age >2 years May be receiving treatment with phosphate and calcitriol, but must be willing to undergo dose adjustments by the investigators if iron resolves the phosphate wasting defect  malignancy within the last 5 years, except treated squamous or basal cell skin carcinoma terminal illness/hospice severe end-organ disease, e.g. cardiovascular, pulmonary, etc, which may limit ability to complete study. estimated GFR <45ml/min/1.73m2, calculated using MDRD formula for adults or modified Schwartz equation for children pregnancy or plan on becoming pregnant
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 1.5-18.0,  Chronic Kidney Disease Renal Transplantation Nephrotic Syndrome Age : between [18 mo et 18 yo[ Patients seen in the paediatric nephrology service and having  Chronic kidney disease Renal transplant Stable nephrotic syndrome (i.e., normal protidemia at inclusion) Initial 25 OH vitamin D concentration < 75nmol/l Patient agree to participate (if old enough to give his agreement) and written informed consent signed by parents Patients affiliated within the French universal healthcare system  Contraindication to 100 000 IU Uvedose® treatment (according to the Summary of Product Characteristics: known hypersensitivity to vitamin D or hypercalcemia, hypercalciuria or nephrolithiasis)
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Healthy Healthy males and females Aged between 20 and 65 years old BMI in the normal range (18.5 to 25.0 kg/m2) Having signed his/her consent form  Clinically relevant digestive (including malabsorption or major surgery), renal, hepatic, pancreatic or metabolic disease (diabetes, hypo or hyperthyroidism, hypo or hypercorticism), as determined by the medical (screening) visit and a standard blood chemistry analysis (glucose, total cholesterol, ALDL, AHDL, triglycerides, ASAT, ALTI, gamma GT, RCRP, creatinine) Medically diagnosed anemia based on a blood formula Food allergy, lactose intolerance and intolerance to milk proteins (anamnesis) Smokers (anamnesis) Pregnancy (anamnesis) Under corticoids or hormone (adrenal, thyroid) treatment Alcohol intake: > 2 units a day (anamnesis) Consumption of illicit drugs (anamnesis) Having given blood within the last month, or willing to make a blood donation until one month following the end of the study Subject who cannot be expected to comply with the study procedures, including consuming the test product